Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Non Operating Income (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Non Operating Income over the past 3 years, most recently at -$39000.0 for Q4 2025.

  • Quarterly results put Non Operating Income at -$39000.0 for Q4 2025, up 85.82% from a year ago — trailing twelve months through Dec 2025 was -$2.8 million (down 81.55% YoY), and the annual figure for FY2025 was -$3.3 million, down 280.05%.
  • Non Operating Income for Q4 2025 was -$39000.0 at Tonix Pharmaceuticals Holding, up from -$1.2 million in the prior quarter.
  • Over the last five years, Non Operating Income for TNXP hit a ceiling of $897000.0 in Q1 2023 and a floor of -$2.0 million in Q2 2025.
  • Median Non Operating Income over the past 3 years was -$41500.0 (2024), compared with a mean of -$212666.7.
  • Biggest five-year swings in Non Operating Income: crashed 4028.57% in 2024 and later skyrocketed 166.44% in 2025.
  • Tonix Pharmaceuticals Holding's Non Operating Income stood at $7000.0 in 2023, then crashed by 4028.57% to -$275000.0 in 2024, then skyrocketed by 85.82% to -$39000.0 in 2025.
  • The last three reported values for Non Operating Income were -$39000.0 (Q4 2025), -$1.2 million (Q3 2025), and -$2.0 million (Q2 2025) per Business Quant data.